UK Markets open in 5 hrs 15 mins
  • NIKKEI 225

    29,438.09
    +276.29 (+0.95%)
     
  • HANG SENG

    28,870.24
    +28.11 (+0.10%)
     
  • CRUDE OIL

    71.30
    +0.42 (+0.59%)
     
  • GOLD FUTURES

    1,862.40
    -3.50 (-0.19%)
     
  • DOW

    34,393.75
    -85.85 (-0.25%)
     
  • BTC-GBP

    28,417.66
    +308.50 (+1.10%)
     
  • CMC Crypto 200

    1,002.88
    +34.04 (+3.51%)
     
  • Nasdaq

    14,174.14
    +104.72 (+0.74%)
     
  • ^FTAS

    4,074.57
    +6.24 (+0.15%)
     

The Amyotrophic Lateral Sclerosis (ALS) Market Forecast to grow at a CAGR of more than 5.5% : Visiongain Research Ltd.

·4-min read

Visiongain has launched a Amyotrophic Lateral Sclerosis (ALS) Market Report 2020-2030, by Treatment (Medication, Stem Cell Therapy, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Others), and Geography.

Visiongain’s industry expert says: ‘The global Amyotrophic Lateral Sclerosis market is anticipated to grow at a lucrative CAGR of more than 5.5% and anticipated to crossUSD 1,000.0 million by 2030.The factors driving this demand are raising geriatric population, growing knowledge of ALS and increasing incidence rate. However, during the projected era, the high cost associated with ALS treatment may pose an impediment for the industry’.

Download Exclusive Sample of Report @ https://www.visiongain.com/report/amyotrophic-lateral-sclerosis-als-market-report-2020-2030/#download_sampe_div

How will the Amyotrophic Lateral Sclerosis (ALS) Market report help you?

In summary, our 200+ page report provides you with the following insight:

• Revenue forecasts to 2030 for 2 segmentations of the Amyotrophic Lateral Sclerosis (ALS) market, with forecasts for Treatment and Distribution Channel each forecasted at a global and regional level– discover the industry’s prospects, finding the most lucrative places for investments and revenues

• Revenue forecasts to 2030 for 4 regional and 13 key national markets – See forecasts for the Amyotrophic Lateral Sclerosis (ALS) market in North America, Europe, Asia-Pacific, and Rest of the World, Also, forecasted are the markets in the U.S., Canada, Germany, France, UK, Italy, France, Spain, China, India, Japan, and Southeast Asia.

• Prospects for established firms and those seeking to enter the market– including company profiles for 10 of the major companies involved in the Amyotrophic Lateral Sclerosis (ALS) market

In terms of region, North America currently holds the largest share of over 50% in ALS market owing to the presence of significant number of patients within the region. Availability of medicines as well as other therapies within the region for disease management is the major reasons for high market share. The factors driving the industry are rise in healthcare spending, attractive reimbursement programs, massive demand for ALS medications and the existing healthcare infrastructure. In 2018, prevalence of ALS in the United States is 5 was 100,000, according to data released in the Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Study.

Get Detailed TOC @ https://www.visiongain.com/report/amyotrophic-lateral-sclerosis-als-market-report-2020-2030/#download_sampe_div

Over the projected era, Asia Pacific is predicted to experience the highest growth rate among all regions. In this area, particularly in India and China, the industry is witnessing a growing revenue generation from Riluzole generic manufacturers. Several of the main drivers of demand growth in this area include increasing R&D spending in the healthcare industryand rise in number of producers and government’s initiatives.

Key vendors in the market include Mitsubishi Tanabe Pharma Corporation, Biohaven Pharmaceutical, AB Science, F.Hoffmann-La Roche AG, and Sun Pharmaceutical. Stem cell therapy providers are also actively performing trials to name a few, BrainStorm Cell Therapeutics, Seneca Biopharma, CORESTEM and many more. However, the Rilutek patent, which was introduced in 1995, expired in 2013, contributing to the development of cheap generic copies of the medication. Companies are pursuing different approaches to achieve a competitive edge, such as innovative product growth, penetration into developing counties and strategic alliances.

Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions.
Visiongain’s study is for everybody needing commercial analyses for the ALSmarket and leading companies. You will find data, trends and predictions.

To access the data contained in this document please email contactus@visiongain.com
Find more Visiongain research reports on Pharmaceutical Industry click on the following links:

Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent market intelligence around, the company publishes hundreds of market research reports which it adds to its extensive portfolio each year. These reports offer in-depth analysis across 18 industries worldwide. The reports cover a 10 year forecasts, are hundreds of pages long, with in-depth market analysis and valuable competitive intelligence data. Visiongain works across a range of vertical markets, which we find currently can influence one another. These markets include automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors. Our customized and syndicated market research reports means that you can have a bespoke piece of market intelligence customized to your very own business needs.

Contact:
Sara Peerun
Commercial Director, UK
Visiongain Limited.
Tel: + 44 207 549 9987
Email: sara.peerun@visiongain.com
Web: https://www.visiongain.com/
Follow Us: LinkedIn | Twitter
-
SOURCE Visiongain Limited.